Best Momentum Stocks to Buy for October 15th
- ORLA, BABA and PDSB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 15, 2024.
- 10/15/2024
|
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
- 100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024
- 10/02/2024
|
PDS Biotechnology: Continuing The Holding Pattern
- PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipeline, while risks involve typical biotech uncertainties and financial sustainability. The bottom-line summary suggests a cautious yet optimistic outlook, emphasizing the importance of upcoming clinical milestones and financial health.
- 09/23/2024
|
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
- PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) during a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain.
- 09/09/2024
|
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
- PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
- 09/03/2024
|
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
- PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the Investor Relations section of the Company's website at www.pdsbiotech.com.
- 08/07/2024
|
PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)
- PDS Biotechnology Corporation (NASDAQ:PDSB ) Clinical Program Update Conference Call August 1, 2024 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Joseph Pantginis - H.
- 08/02/2024
|
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
- Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J.
- 08/01/2024
|
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
- PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to provide a clinical program update on Thursday, August 1, 2024, at 8:00 a.m. ET.
- 07/31/2024
|
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
- Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
- 05/15/2024
|
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
- 30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, hosted a Key Opinion Leader event on May 8, 2024 during which prominent experts in head and neck squamous cell cancer (“HNSCC”) discussed positive, updated VERSATILE-002 data and the unmet need in HPV16-positive HNSCC.
- 05/09/2024
|
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
- PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the first quarter of 2024 and provide a business update on Wednesday, May 15, 2024, before the market opens. The press release will be available in the Investor Relations section of the Company's website at www.pdsbiotech.com.
- 05/07/2024
|
PDS Biotechnology Announces Details of Virtual KOL Event
- Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024 Virtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024
- 05/03/2024
|
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
- PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced the appointment of Stephan Toutain, MS, MBA, as Chief Operating Officer (COO), effective as of May 1, 2024.
- 05/02/2024
|
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
- Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial
- 04/23/2024
|
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
- PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
- 03/27/2024
|
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
- Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial
- 03/27/2024
|
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
- PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell-activating platforms, today announced that the Company will provide a business update and release financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Following the release, management will host a conference call to review the financial results and provide a business update.
- 03/20/2024
|
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
- Biotech stocks are not for investors with a low-risk tolerance. This sector has stocks that are either considered blue-chip names or pre-revenue lotto tickets.
- 03/13/2024
|
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
- Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants
- 03/13/2024
|
PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data
- Preliminary efficacy results from phase 1/2 Mayo Clinic study, using PDS0101 + KEYTRUDA to treat patients with Oropharyngeal cancer, expected in Q2 2024. The global oral cancer treatment market is expected to reach $2.74 billion by 2030. It is said that nearly 80% to 90% of all oropharynx tumors are HPV-positive.
- 01/26/2024
|
PDS Biotech Announces Retirement of Lauren V. Wood, M.D.
- Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company
- 01/22/2024
|
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
- PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference taking place virtually on Thursday, January 18, 2024, at 10:00 AM EST. Details are as follows:
- 01/16/2024
|
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
- PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 01/02/2024
|
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today that on December 4, 2023, PDS Biotech granted nonstatutory stock options to Lars Boesgaard, the Company's new Chief Financial Officer, to purchase a total of 200,000 shares of the Company's common stock as a material inducement to Mr. Boesgaard's employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019 and provides for the granting of equity awards to new employees of PDS Biotech.
- 12/04/2023
|
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
- PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced the appointment of Lars Boesgaard as Chief Financial Officer (CFO), effective as of December 4, 2023. Mr. Boesgaard succeeds Matthew Hill, who resigned as PDS Biotech's CFO on November 21, 2023, effective December 1, 2023, to pursue other professional endeavors.
- 11/28/2023
|
PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript
- PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Nicole Jones - Investor Relations Frank Bedu-Addo - Chief Executive Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Joe Pantginis - HC Wainwright Laura Suriel - Alliance Resource Partners Operator Greetings and welcome to the PDS Biotechnology Third Quarter 2023 Earnings Call and Webcast.
- 11/14/2023
|
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
- PRINCETON, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced its financial results for the quarter ended September 30, 2023. The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
- 11/14/2023
|
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
- PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301 (IL-12 antibody-drug conjugate) and an investigational immune checkpoint inhibitor (ICI) in two groups of advanced cancer patients with various types of human papillomavirus (HPV) 16-positive cancers. The ICI naïve group had not responded to standard-of-care treatments but had not yet been treated with an ICI. The ICI resistant group included patients who had not responded to multiple prior treatments, including ICI therapy. Investigators at the National Cancer Institute (NCI), part of the National Institutes of Health, have completed the primary endpoint analysis of the Phase 2 trial.
- 11/09/2023
|
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
- PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that the Company will release financial results for the third quarter of 2023 on Tuesday, November 14, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
- 11/07/2023
|
PDS Biotech to Present at the LD Micro Main Event XVI
- PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that Frank Bedu-Addo, PhD, Chief Executive Officer of PDS Biotech, will present at the LD Micro Main Event XVI being held on October 3-5, 2023, in Los Angeles, CA. Details for the event are as follows:
- 09/26/2023
|
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that Frank Bedu-Addo, PhD, Chief Executive Officer of PDS Biotech, will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference being held September 26-28, 2023, in New York City. Details for the event are as follows:
- 09/20/2023
|
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
- PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech, will participate and present an overview of the company and its programs at the H.C. Wainwright 25th Annual Global Investment Conference.
- 09/06/2023
|
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
- Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.
- 08/29/2023
|
PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
- PDS Biotechnology has achieved positive results in its phase 2 study of PDS0101 in combination with Merck's Keytruda for HPV16-positive head and neck cancer. The interim analysis showed 9 confirmed responses, which increased to 14 in a later update, surpassing the efficacy threshold for the study. PDS plans to submit an amended IND application to the FDA in Q3 2023 to initiate its phase 3 VERSATILE-003 study.
- 08/14/2023
|
The Prognosis For PDS Biotechnology
- PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeline and is well-liked within the analyst firm community. With two registrational studies on the horizon, it seems a good time to 'circle back' on this small developmental, oncology-focused concern.
- 08/13/2023
|
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
- PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that the Company will release financial results for the second quarter of 2023 on Monday, August 14, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
- 08/07/2023
|
PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023
- PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced that Dr. Frank Bedu-Addo, Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2023 being held August 7-8, 2023. Details for the event are as follows:
- 08/02/2023
|
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
- FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference call and webcast tomorrow, June 6, 2023, to discuss the promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), presented at the 2023 American Society for Clinical Oncology (ASCO) meeting.
- 06/05/2023
|
PDS Biotechnology: Promising Interim HNSCC Data Reaffirms Investment Prospects
- PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical rates from similar treatments.
- 05/27/2023
|
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
- PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients.
- 05/26/2023
|
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
- PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer patients.
- 05/19/2023
|
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
- FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results for the first quarter of 2023 on Monday, May 15, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
- 05/04/2023
|
PDS Biotechnology: Late-Stage Biotech With Enormous Potential
- PDS Biotechnology: Late-Stage Biotech With Enormous Potential.
- 04/26/2023
|
PDS Biotechnology Corporation (PDSB) Q4 2022 Earnings Call Transcript
- PDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2022 Results Earnings Conference Call March 28, 2023 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Leland Gershell - Oppenheimer & Co. Louise Chen - Cantor Fitzgerald Andrew Fleszar - B. Riley Securities James Molloy - Alliance Global Partners Robert LeBoyer - Noble Capital Markets Operator Greetings.
- 03/28/2023
|
5 Best and Worst Performing Small-Cap Stocks in Q4 2022
- The fourth quarter of 2022 was relatively better for the stock markets, with the S&P 500 up over 7% (its only positive quarterly return for the year).
- 01/26/2023
|
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
- A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.
- 12/29/2022
|
PDS Biotechnology's latest trial reports improved survival in advanced cancer patients
- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company owned by NetScientific, has reported expanded interim data from a Phase-2 clinical trial of its PDS0101 triple combination therapy for advanced, refractory human papillomavirus (HPV)-positive cancers. All patients in the study had failed prior treatment with chemotherapy and 90% had failed radiation treatment.
- 12/28/2022
|
PDS Biotechnology Corporation (PDSB) Q3 2022 Earnings Call Transcript
- PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matt Hill - Chief Financial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Laura Suriel - Alliance Global Partners Robert LeBoyer - Noble Capital Operator Greetings. Welcome to PDS Biotech's Third Quarter 2022 Earnings Conference Call and Webcast.
- 11/14/2022
|
PDS Biotech: Strong Data Indicate Further Upside
- As it successfully pivoted into immuno-oncology, PDS is making big waves in this therapeutic development space. The premier drug development platform (Versamune) already generated extremely robust early data for various cancers.
- 10/24/2022
|
Netsceintific pleased with progress at PDS Biotech
- Netscientific PLC said it was encouraged by the progress being made at PDS Biotech after the US portfolio company released second-quarter results yesterday. Ilian Iliev, NetScientific's CEO, added: "We are pleased with the continued progress by PDS Biotech in its Phase 2 trials and broader corporate development, coming despite the ongoing volatility in the biotech public markets.
- 08/09/2022
|
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2022 Results - Earnings Call Transcript
- PDS Biotechnology Corporation (NASDAQ:PDSB ) Q2 2022 Results Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald James Molloy - Alliance Global Partners Leland Gershell - Oppenheimer & Co. Joseph Pantginis - H. C. Wainwright & Co. Robert LeBoyer - Noble Capital Markets Operator Greetings.
- 08/08/2022
|
PDS Biotechnology Gains On FDA Fast Track Designation For Lead Candidate
- The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PDS Biotechnology's (NASDAQ: PDSB) lead drug candidate PDS0101 in combination with KEYTRUDA (pembrolizumab) for the treatment of patients with recurrent or metastatic HPV16-positive head and neck cancer.
- 06/02/2022
|
PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
- Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients.
- 05/27/2022
|
PDS Biotech to Participate at Upcoming Investor Conferences
- FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that its management will present at the H.C. Wainwright Global Investment Conference and the LD Micro Invitational and will participate at the UBS Healthcare Virtual One-on-One Day.
- 05/17/2022
|
NetSceintific highlights PDS Biotech's key posters at upcoming ASCO conference
- NetScientific PLC (AIM:NSCI) has noted first-quarter results from its portfolio company PDS Biotechnology, which also has results from key trials upcoming at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in June. Abstract # 6041 will summarize updates to the preliminary efficacy and safety data from the PDS-sponsored VERSATILE-002 Phase 2 clinical trial, which is evaluating PDS0101 in combination with Merck's anti-PD-1 therapy KEYTRUDA for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.
- 05/11/2022
|
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q1 2022 Results - Earnings Call Transcript
- PDS Biotechnology Corporation. (NASDAQ:PDSB ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Leland Gershell - Oppenheimer Laura Suriel - Alliance Global Partners Robert LeBoyer - Noble Capital Operator Hello and welcome to PDS Biotechnology First Quarter 2022 Earnings Call and Webcast.
- 05/11/2022
|
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2021 Results - Earnings Call Transcript
- PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2021 Results - Earnings Call Transcript
- 03/31/2022
|
NetSceinttific notes 'steady progress' by portfolio company PDS
- NetScientific PLC (AIM:NSCI) says its portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB) (Nasdaq: PDSB), made good progress through 2021, hitting a number of milestones. Ilian Iliev, NetScientific chief executive, said: "PDS has continued the steady progress and build-out of the business, progressing multiple clinical applications of the Versamune platform in immuno-oncology and infectious disease vaccines.
- 03/31/2022
|
PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call
- FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that it has changed the date of its previously announced 2021 fourth quarter and full year earnings release call from Wednesday, March 23, 2022 to 8:00 AM EDT on Thursday, March 31, 2022 as PDS Biotech needs additional time to complete its audit and file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Following the release, management will host a conference call to review the financial results and provide a business update.
- 03/22/2022
|
PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
- PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
- 02/21/2022
|
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q3 2021 Results - Earnings Call Transcript
- PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference
- FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the company's Chief Medical Officer, Dr. Lauren V. Wood, will be presenting at the upcoming 2021 International Head and Neck Cancer Conference hosted by Cardiff, NHS Wales and The Swallows Head & Neck Cancer Support Group.
- 10/27/2021
|
PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results
- FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, will release financial results for the third quarter of 2021 on Wednesday, November 10, 2021, before the market opens. Following the release, management will host a conference call to review the company's financial results and provide a business update.
- 10/13/2021
|
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer
- No dose limiting toxicities observed in initial group of 12 patients No dose limiting toxicities observed in initial group of 12 patients
- 09/20/2021
|
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced that the compensation committee of the board of directors of the Company approved, on September 13, 2021, an equity award to Gregory Reid, the Company's new VP of Program Development, as a material inducement to Mr. Reid entering into employment with PDS Biotech.
- 09/15/2021
|
Best Penny Stocks To Buy In 2021? 5 That Turned $2,500 Into $26,000
- Were these penny stocks on your list this year? The post Best Penny Stocks To Buy In 2021?
- 09/13/2021
|
PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
- FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, announced today that its management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
- 09/13/2021
|
PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference
- FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.
- 09/07/2021
|
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2021 Results - Earnings Call Transcript
- PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results
- FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call today.
- 08/12/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of PDS Biotechnology Corporation - PDSB
- New York, New York--(Newsfile Corp. - July 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of PDS Biotechnology Corporation (NASDAQ: PDSB) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/pds-biotechnology-corporation-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
- 07/12/2021
|
PDS Biotechnology Joins Russell Microcap® Index
- FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, was added to the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective on June 28, according to the FTSE Russell website.
- 07/01/2021
|
NetScientific gives further backing to PDS Biotechnology
- NetScientific PLC (LON:NSCI) said its portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB), has closed its underwritten public offering of shares. The shares were offered at US$8.50 a pop.
- 06/22/2021
|
PDSB Stock Price Increases Over 15%: Why It Happened
- The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by over 15% during intraday trading. This is why it happened.
- 06/18/2021
|
PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
- FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 6,088,235 shares of common stock (inclusive of the 794,117 shares that were sold pursuant to the underwriter's full exercise of its option to purchase additional shares of common stock) at a public offering price of $8.50 per share. Certain insiders, including certain members of the Company's board of directors and executive officers, purchased shares of PDS Biotech common stock in the offering.
- 06/17/2021
|
NetScientific: City broker provides thumbs up following PDS funding round
- WH Ireland applauded the progress of NetScientific PLC (LON:NSCI) investee company PDS Biotechnology Corporation (NASDAQ: PDSB), which has unveiled plans to raise US$45mln. The broker said the latest funding round underlined investor confidence in the prospects for PDS and interest in its immuno-oncology platform, Versamune.
- 06/16/2021
|
NetScientific follows its money as investee company announces plans to raise US$45mln
- NetScientific PLC (LON:NSCI) said it is participating in the latest funding round by investee company PDS Biotechnology Corporation (NASDAQ:PDSB). It said it is buying shares worth US$510,000 and is funding the transaction from a loan facility.
- 06/16/2021
|
PDS Biotech Announces Proposed Offering of Common Stock
- FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by PDS Biotech. PDS Biotech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 06/14/2021
|
Why PDSB Shares Are Trading Higher Today
- PDS Biotechnology Corp (NASDAQ:PDSB) shares are trading higher by 13.3% at $10.65 Tuesday morning after the company highlighted the release of interim data for PDS0101 in an NCI-led Phase 2 clinical study in oral presentation at the ASCO 2021 annual meeting. PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States.
- 06/08/2021
|
NetScientific on the rise again after PDS cancer trial
- NetScientific PLC (LON:NSCI) portfolio company, PDS Biotechnology (NASDAQ:PDSB) said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression. Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, the data showed results of a phase PDS's candidate PDS0101 in combination with two immune-modulating agents on 25 patients.
- 06/08/2021
|
NetScientific PLC on the rise aagain after PDS cancer trial
- NetScientific PLC (LON:NSCI) portfolio company, PDS Biotechnology (NASDAQ:PDSB) said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression. Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, the data showed results of a phase PDS's candidate PDS0101 in combination with two immune-modulating agents on 25 patients.
- 06/08/2021
|
CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
- Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy
- 06/08/2021
|
PDS Biotech's Lead Versamune Program Achieves Overall Tumor Reduction of 67% In HPV16 Positive Cancer Patients
- PDS Biotechnology Corporation (NASDAQ: PDSB) has announced interim data from the Phase 2 trial led by the National Cancer Institute (NCI) evaluating PDS0101 (Versamune-HPV16) in combination with two investigational immune-modulating agents - bintrafusp alfa and NHS-IL12 for HPV16 positive cancers. Data were presented at the American Society of Clinical Oncology 2021 Annual Meeting.
- 06/08/2021
|
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
- Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy
- 06/08/2021
|
PDS Biotech Shines At The ASCO 2021 Annual Meeting
- PDSB has gained over 125% since clinical data in an ASCO abstract on its lead cancer therapeutic was published. The company still has lots of room for growth if its lead therapeutic candidate is eventually approved to treat HPV-associated cancers.
- 06/03/2021
|
PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors
- FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced the protocol amendment to expand its Phase 2 VERSATILE-002 study to include patients, in an additional arm, who have failed prior checkpoint inhibitor (CPI) therapy (CPI refractory patients). The VERSATILE-002 study is designed to evaluate PDS0101 in combination with KEYTRUDA® (pembrolizumab) in the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer and is currently being run at approximately 20 clinical sites in the US.
- 06/03/2021
|
PDS Biotech to Host Oncology R&D Day on June 16, 2021
- FLORHAM PARK, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community from 8:00 – 10:00 AM ET on Wednesday, June 16th.
- 06/01/2021
|
Implied Volatility Surging for PDS Biotechnology (PDSB) Stock Options
- Investors need to pay close attention to PDS Biotechnology (PDSB) stock based on the movements in the options market lately.
- 05/24/2021
|
Implied Volatility Surging for PDS Biotechnology (PDSB) Stock Options
- Investors need to pay close attention to PDS Biotechnology (PDSB) stock based on the movements in the options market lately.
- 05/24/2021
|
PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting
- FLORHAM PARK, N.J., May 24, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced that they will host a company conference call on June 8, 2021 at 8:00 am ET, following the oral presentation of preliminary data of PDS0101 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. A press release summarizing the abstract data was issued on May 20.
- 05/24/2021
|
PDSB Stock Price: Over 6% Increase Pre-Market Explanation
- The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by over 6% pre-market. This is why it happened.
- 05/24/2021
|
PDSB Stock Price: 14.58% Increase Explanation
- The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by 14.58% on Friday, May 21. This is why it happened.
- 05/23/2021
|
Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 05/22/2021
|
NetScientific hails the potential of investee company's cancer immunotherapy
- NetScientific PLC (LON:NSCI) said an investee company will share additional data that will underline the potential efficacy of a breakthrough cancer immunotherapy. PDS Biotechnology Corporation (NASDAQ:PDSB) will use its presentation at the prestigious American Society of Clinical Oncology (ASCO) annual meeting next month to reveal it has observed a 10-out-of-14, or 71% response rate to lead drug PDS0101.
- 05/21/2021
|
PDS Biotechnology (PDSB) Stock: 26.66% Increase Explanation
- The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by 26.66% today. This is why it happened.
- 05/20/2021
|
Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021
- Penny stocks that left the nest in 2021 To Watch Right Now The post Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/20/2021
|
PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting
- Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63% (5 of 8) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63% (5 of 8) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy
- 05/20/2021
|
NetScientific portfolio firm PDS Biotech sells off New Jersey tax benefits
- NetScientific PLC (LON:NSCI) said its portfolio firm, PDS Biotechnology Corp (NASDAQ:PDSB), it which it owns a 5.75% stake, has received US$4.5mln from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the company's participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for 2020. The NOL program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 U.
- 05/18/2021
|
PDS Biotechnology Corp (PDSB) CEO Frank Bedu-Addo on Q1 2021 Results - Earnings Call Transcript
- PDS Biotechnology Corp (PDSB) CEO Frank Bedu-Addo on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results
- FLORHAM PARK, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended March 31, 2021 and provide a business update on its conference call today.
- 05/13/2021
|
PDS Biotech Advances the Fight Against Cancer with its Versamune® Platform
- PDS Biotechnology Corporation (NASDAQ: PDSB) will be reporting preliminary Phase 2 clinical data of its lead compound PDS0101 for the treatment of advanced HPV-associated cancers in patients whose cancer has returned or progressed after treatment at the upcoming American Society of Clinical Oncology (ASCO) 2021 Annual Meeting on June 4-8. The study is being performed under a collaboration agreement with the National Cancer Institute (NCI).
- 05/03/2021
|
PDS Biotechnology Announces Conference Call and Webcast for First Quarter Financial Results
- FLORHAM PARK, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the first quarter of 2021 on Thursday, May 13, 2021, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
- 04/26/2021
|
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2020 Results - Earnings Call Transcript
- PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2020 Results - Earnings Call Transcript
- 03/18/2021
|
PDSB Stock: Why PDS Biotech Is Blasting Higher Today
- PDS Biotech (PDSB) stock is heading higher on Thursday after announcing funding for the company's vaccine for the novel coronavirus. The post PDSB Stock: Why PDS Biotech Is Blasting Higher Today appeared first on InvestorPlace.
- 03/11/2021
|
PDSB Stock Price Increases Over 20% Pre-Market: Why It Happened
- The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) has increased by over 20% pre-market. This is why it happened.
- 03/11/2021
|
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with an Award of up to Approximately US$60 million
- Development and commercialization of novel T-cell activating vaccine to be performed in Brazil by consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica Development and commercialization of novel T-cell activating vaccine to be performed in Brazil by consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica
- 03/11/2021
|
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2020 Financial Results
- FLORHAM PARK, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the three- and twelve-month periods ended December 31, 2020 on Thursday, March 18, 2021, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
- 03/08/2021
|
PDS Biotech Announces Presentations in Upcoming Healthcare Investor Conferences
- FLORHAM PARK, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, and at the 31st Annual Oppenheimer Healthcare Conference being held from March 16-18. Both conferences are being hosted virtually.
- 03/03/2021
|
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine
- Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin America Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin America
- 02/22/2021
|
PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology
- Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment
- 01/14/2021
|
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- FLORHAM PARK, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the Compensation Committee of the PDS Board of Directors approved the grant of inducement stock options covering an aggregate of 202,800 shares of PDS Biotech's common stock to the newly appointed Chief Financial Officer, Seth Van Voorhees in accordance with Nasdaq Listing Rule 5635(c)(4).
- 01/06/2021
|
PDS Biotech Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
- FLORHAM PARK, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that Chief Executive Officer Dr. Frank Bedu-Addo will be presenting at H.C. Wainwright's BioConnect virtual conference. PDS Biotech's presentation will be available on-demand beginning January 11, 2021 at 6:00 AM ET and can be accessed online here.
- 01/05/2021
|
PDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer
- FLORHAM PARK, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced the appointment of Seth Van Voorhees, Ph.D. as its new Chief Financial Officer effective January 1, 2021.
- 12/09/2020
|
Where Do Hedge Funds Stand On PDS Biotechnology Corporation (PDSB)?
- Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in PDS Biotechnology Corporation (NASDAQ:PDSB)? The smart money sentiment can provide an answer to this question.
- 11/27/2020
|
PDS Biotech Announces New and Broad Versamune® Platform Patent Claims
- Granted methods patent for Versamune® platform by the United States Patent and Trademark Office Granted methods patent for Versamune® platform by the United States Patent and Trademark Office
- 11/16/2020
|
PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine
- PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency
- 11/10/2020
|
PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck
- VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients
- 11/09/2020
|
PDS Biotechnology Announces Feature in “Grand Rounds” Webinar hosted by Alliance Global Partners and Conference Call and Webcast for Third Quarter 2020 Financial Results
- FLORHAM PARK, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the Company will be featured in a live webinar, “Grand Rounds: A Webinar in Biotech and Specialty Pharma,” hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners, on Monday, November 2nd at 10:30 am Eastern Time.
- 10/29/2020
|
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer
- PDS Biotech progresses second Phase 2 human clinical trial of PDS0101 PDS Biotech progresses second Phase 2 human clinical trial of PDS0101
- 10/26/2020
|
PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
- FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of common stock (inclusive of the 900,000 shares that were sold pursuant to the underwriter’s full exercise of its option to purchase additional shares of common stock) at a public offering price of $2.75 per share. Certain insiders, including certain of the Company’s officers, purchased shares of PDS Biotechnology common stock in the offering. The gross proceeds to PDS Biotechnology from this offering, before deducting underwriting discounts, commissions and other offering expenses were approximately $19.0 million.Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering.The shares of common stock described above were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-240011) previously filed with the U.S. Securities and Exchange Commission (“SEC”) on July 22, 2020 and declared effective on July 31, 2020, and the accompanying prospectus contained therein. The offering of the shares of common stock was made by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website, located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Oppenheimer & Co. Inc. at 85 Broad Street, 26th Floor, New York, NY 10004, Attention: Equity Syndicate Prospectus Department, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About PDS BiotechnologyPDS Biotechnology is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotechnology has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.Forward Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotech’s filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotechnology undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.Media & Investor Relations Contact:Deanne Randolph PDS Biotechnology Phone: +1 (908) 517-3613 Email: drandolph@pdsbiotech.comAlexander Lobo The Ruth Group Phone: +1 (646) 536-7037 Email: alobo@theruthgroup.com
- 08/13/2020
|
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2020 Results - Earnings Call Transcript
- PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2020 Earnings Conference Call August 13, 2020 08:00 ET Company Participants Deanne Randolph - Investor Relations Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Michael King - Interim Chief Financial Officer Conference Call Participants Presentation Operator Greetings, and welcome to PDS Biotechnology's Second Quarter 2020 Financial Results.
- 08/13/2020
|
PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update
- FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the second quarter ended June 30, 2020 and provided a business update. Second Quarter 2020 and Recent Business Highlights * Announced publication of PDS0101 triple combination preclinical study by the National Cancer Institute; * Initiated Phase 2 clinical trial of PDS0101 triple combination, led by the National Cancer Institute, for the treatment of advanced human papillomavirus (HPV)-associated cancers; * Announced Phase 2 trial to evaluate PDS0101 in combination with standard of care for treatment of locally advanced cervical cancer at The University of Texas MD Anderson Cancer Center; * Launched novel PDS Biotech-owned vaccine development programs for COVID-19, PDS0203, and universal influenza, PDS0202; * Broadened existing co-development agreement with Farmacore Biotechnology to include development of a second COVID-19 vaccine candidate, PDS0204; * Expanded existing Cooperative Research and Development Agreement with the National Cancer Institute to include preclinical and clinical development of PDS0103 in MUC-1 expressing- cancers including breast, colon, lung and ovarian cancers; * PDS Biotech collaborator at the University of Kentucky School of Medicine granted NIAID award to accelerate Versamune®-based PDS0202 universal influenza vaccine; * Published abstract on preclinical studies of PDS0102, a product for the treatment of breast and prostate cancers, at the American Society of Clinical Oncology; and * Appointed Dr. Ilian Iliev to Board of Directors.“PDS Biotech has made significant progress across both our immuno-oncology and infectious disease programs despite the challenging environment due to the global pandemic,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech. “We are pleased despite the pandemic to have recently initiated our first of three Phase 2 clinical studies of PDS0101. This study is being run by the National Cancer Institute for the treatment of advanced HPV-associated cancers. We anticipate initiation in the near term a second Phase 2 study for PDS0101 with standard of care chemoradiotherapy at the MD Anderson Cancer Center for the treatment of locally advanced cervical cancer. We believe these trials, partnered with leading organizations hold significant potential to demonstrate that our Versamune® platform, in combination with other anti-cancer agents, will provide improved clinical outcomes for patients with advanced HPV-associated cancers. We are evaluating the potential to initiate the VERSATILE-002 trial that was put on hold due to the COVID-19 epidemic by the end of the year if possible.”“We have also been conducting preclinical studies of PDS0203, our COVID-19 vaccine program and recently announced an expanded development collaboration with Farmacore to advance PDS0204, a second COVID-19 vaccine candidate into Phase 1 clinical testing in Brazil, with initial financial support for preclinical work provided by the Brazilian Ministry of Science, Technology, Innovation and Communication (MCTIC). Furthermore, the grant by the NIAID to our long-term collaborator at The University of Kentucky School of Medicine to accelerate the Versamune®-based universal influenza vaccine program, PDS0202, further validates the potential value of Versamune® in infectious diseases. With these significant developments in both our cancer and infectious disease programs, we believe that PDS Biotech is well positioned to progress our programs through initial human clinical data generation over the next 12-18 months, barring any unforeseen events,” concluded Dr. Bedu-Addo.Second Quarter 2020 Financial ReviewFor the second quarter of 2020, net loss was approximately $2.9 million, or $.19 per basic share and diluted share, compared to a net loss of approximately $3.9 million, or $0.75 per basic share and diluted share for the second quarter of 2019.Research and development expenses totaled approximately $1.4 million for the second quarter of 2020, compared to approximately $1.9 million for the same period in 2019, a decrease of 26%.For the second quarter of 2020, general and administrative expenses were approximately $1.5 million compared with approximately $2.4 million for the second quarter of 2019, a decrease of 38%.Total operating expenses for the second quarter of 2020 were approximately $2.9 million, compared to total operating expenses of approximately $4.3 million for the same period in 2019, a decrease of 33%.As of June 30, 2020, the Company’s cash balance was approximately $16.9 million.Conference Call and WebcastThe conference call is scheduled to begin at 8:00 am ET on Thursday, August 13, 2020. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.pdsbiotech.com.After the live webcast, the event will be archived on PDS Biotech’s website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13707451.About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. All such written or oral statements made in this press release, filings with the Securities and Exchange Commission, reports to stockholders and in meetings with investors and analysts, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast.” “guidance”, “outlook” and other similar expressions or words that convey uncertainty of future events or outcomes. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; our dependence on additional financing to fund our operations and complete the development and commercialization of our product candidates, and the risks that raising such additional capital may restrict our operations or require us to relinquish rights to our technologies or product candidates; our limited operating history in our current line of business, which makes it difficult to evaluate our prospects, our business plan or the likelihood of our successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S.
- 08/13/2020
|
PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock
- FLORHAM PARK, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the pricing of its previously announced underwritten public offering consisting of 6,000,000 shares of common stock at a public offering price of $2.75 per share. The gross proceeds to PDS Biotech from this offering are expected to be $16,500,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, PDS Biotech has granted the underwriter a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on Thursday, August 13, 2020, subject to customary closing conditions. PDS Biotech intends to use the proceeds from this offering to fund working capital and general corporate purposes.Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering.This offering by PDS Biotech is being made pursuant to an effective registration statement on Form S-3 (File No. 333-240011) previously filed with the U.S. Securities and Exchange Commission ("SEC") on July 22, 2020 and declared effective on July 31, 2020, and the accompanying prospectus contained therein. The offering of the shares of common stock will be made by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC, and will be available on the SEC's website at http://www.sec.gov or by contacting Oppenheimer & Co. Inc. at 85 Broad Street, 26th Floor, New York, NY 10004, Attention: Equity Syndicate Prospectus Department, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. Forward Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotech’s filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotech undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.Media & Investor Relations Contact:Deanne Randolph PDS Biotechnology Phone: +1 (908) 517-3613 Email: drandolph@pdsbiotech.com Alexander Lobo The Ruth Group Phone: +1 (646) 536-7037 Email: alobo@theruthgroup.com
- 08/11/2020
|
PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock
- FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by PDS Biotech. PDS Biotech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. PDS Biotech intends to use the proceeds from this offering to fund working capital and general corporate purposes.Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering.This offering by PDS Biotech is being made pursuant to an effective registration statement on Form S-3 (File No. 333-240011) previously filed with the U.S. Securities and Exchange Commission ("SEC") on July 22, 2020 and declared effective on July 31, 2020, and the accompanying prospectus contained therein. The offering of the shares of common stock will be made by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC, and will be available on the SEC's website at http://www.sec.gov or by contacting Oppenheimer & Co. Inc. at 85 Broad Street, 26th Floor, New York, NY 10004, Attention: Equity Syndicate Prospectus Department, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.Before investing in this offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that PDS Biotech has filed with the SEC that are incorporated by reference in the preliminary prospectus supplement and the accompanying prospectus, which provide more information about PDS Biotech and such offering.This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. Forward Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotech’s filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotech undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.Media & Investor Relations Contact:Deanne Randolph PDS Biotechnology Phone: +1 (908) 517-3613 Email: drandolph@pdsbiotech.comAlexander Lobo The Ruth Group Phone: 1 (646) 536-7037 Email: alobo@theruthgroup.com
- 08/10/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
3 “Strong Buy” Healthcare Stocks Under $5 That Could See Outsized Gains
- The stock market just keeps going up, up and away. COVID-19 continues to have a choke hold on the economy, yet stocks have pulled off an incredible recovery, with the S&P 500 up 50% since its March low point. But can the index keep the rally alive?Credit Suisse’s global equity strategy analyst Andrew Garthwaite says yes, noting that by the end of next year, the S&P 500 could “easily hit 3,500 on our models.” He believes there won’t be a major correction, and that “the key is whether you want to buy into dips or sell into rallies and we want to buy into dips.”Why should investors keep buying? “We’re going to get a combination of easy money, easy fiscal, with yield curve control — i.e. fiscal QE [quantitative easing] — until unemployment returns to politically acceptable levels,” Garthwaite explained.Against this backdrop, Wall Street pros argue that certain sectors are holding up substantially better than the rest, and within these areas, compelling plays can be found. Highlighting the healthcare space, the pros say there are names that have not only received a lot of love from the analyst community, but also stand to deliver hefty returns through 2020 and beyond.As these stocks tend to be riskier in nature, we narrowed our search to include only the best of the best, according to the analyst community. TipRanks’ database revealed three such stocks that won’t break the bank.; each one trades for less than $5 per share and has earned a “Strong Buy” consensus rating from the Street’s pros. If that wasn’t enough, plenty of upside potential is at play here. Gritstone Oncology Inc. (GRTS)With the goal of stomping out cancer once and for all, Gritstone Oncology develops personalized immunotherapies to fight multiple cancer types. Currently going for $3.45 apiece, several members of the Street believe that the share price reflects an attractive entry point.Looking at the company’s clinical activity, GRTS is conducting a Phase 1 dose escalation of its GRANITE (personalized vacccine targeting cancer neoantigens) and SLATE (off-the-shelf cancer vaccine targeting shared “hotspot” neoantigens) in patients with advanced cancer. Updated data from July indicated that some patients had experienced prolonged stable disease and/or tumor regression, but none had risen to the level of a RECIST response.Weighing in on the results for H.C. Wainwright, analyst Sean Lee wrote, “In our view, GRANITE and SLATE are both safe and showed encouraging signs of efficacy, which should warrant further study in larger patient populations. Both GRANITE and SLATE are well-tolerated, and as of the June 30 data cut-off date, zero dose limiting toxicities (DLTs) have been reported in the GRANITE study and only two DLTs had been reported in the SLATE study... Therefore, we believe the 50% decline in GRTS stock price on July 13 to be an overreaction which has created an attractive buying opportunity.”Going forward, GRTS will kick off single-arm Phase 2 studies for both GRANITE and SLATE in advanced cancer in 2H20. For GRANITE, the study will include two cohorts of MSS-CRC patients with prior FOLFOX/FOLFIRI therapy and GEA patients with prior chemotherapy. Based on the fact that checkpoint inhibitors have either no (MSS-CRC) or very little (GEA) activity in GI tumors, management has stated that if multiple responses in these cohorts are observed, it would demonstrate additive efficacy and could ultimately support accelerated approval.As for SLATE, GRTS is set to evaluate the original cassette of SLATE (Cassette v1) in ovarian cancer patients with the TP53 mutation and NSCLC patients with prior immunotherapy/chemotherapy. A new version of the SLATE cassette (Cassette v2) designed to optimize the immune response to KRAS mutations will also be assed.“The Phase 2 GRANITE study is expected to report data in 2H21, and the results from Phase 2 studies of SLATE Cassette v1 and Cassette v2 are anticipated in 1H21 and 2H21, respectively. In our view, all of these could be major catalysts for the stock,” Lee commented.To this end, LEE rates GRTS a Buy along with a $16 price target. Should his thesis play out, a potential twelve-month gain of 365% could be in the cards. (To watch Lee’s track record, click here) Other analysts are also optimistic about the stock. GRTS' Strong Buy consensus rating breaks down into 3 Buys and no Holds or Sells. In addition, the $14 average price target brings the upside potential to 307%. (See GRTS stock analysis on TipRanks)PDS Biotechnology Corporation (PDSB)Using its patented Versamune platform, PDS Biotechnology develops innovative infectious disease (ID) vaccines and cancer immunotherapies. Based on its impressive technology platform and $4.35 share price, it’s no wonder this name is scoring the Street’s attention.5-star analyst Geulah Livshits, of Chardan Capital, is even more optimistic after a recent call with PDSB’s CMO Dr. Lauren Wood.Highlighting the takeaways from the call, Livshits points out that it’s important to consider the similarities between cancer and ID pathogens. Part of the problem when it comes to developing cancer-targeting vaccines is that many cancer antigens are also present in normal tissue, with the immune system failing to view these self-antigens as foreign. “As such, a key gating factor for developing cancer vaccines, which can translate over to ID vaccine development, is triggering innate immunity (specifically type I interferon signals),” the analyst explained.According to Dr. Wood, T cell responses are often longer-lived than antibody responses. Livshits wrote, “Although the field does not yet fully understand what that means for immunity duration (or indeed what titer levels are sufficient for protection from SARS-CoV-2), the efficient induction of a high quality T cell response may promote longer lasting immune memory, potentially translating to longer protection or a milder disease course upon subsequent exposure.”That’s where PDSB comes in. Versamune is an adjuvant designed to overcome the mechanisms that suppress the innate immune response, specifically triggering type I interferons. In both cancer and ID, Versamune triggers “excellent presentation of antigens” by both the class I and class II pathways, creating potent, broad and long-lived T cell responses, as well as antibody responses.Also encouraging, the platform can stimulate the immune system locally (in the skin) when delivered, with Dr. Wood also noting that “Versamune's adjuvant tech can be co-formulated and delivered with other platforms beyond protein/peptides, including DNA or mRNA, to enhance immunogenicity.”Looking at its performance in a clinical setting, there has been a documented triggering of type I interferons associated with HPV tumor regression in a clinical mouse model, verified immune memory demonstrated by mice resistant to tumor re-challenge, high levels of specific CD8 killer T cells within two weeks of a single dose of vaccine and T cell regression of virus-mediated lesions. Versamune has also been well tolerated.Adding to the good news, in preclinical studies, when Versamune was co-delivered with Fluzone, a seasonal influenza vaccine, neutralizing antibody titers were 40x higher compared to Fluzone alone. Livshits added, “With regard to SARS-CoV-2, initial preclinical data in mice show the Versamune-based Covid-19 vaccine candidate induces robust neutralizing antibody response levels equivalent to those observed in recovering Covid-19 patients within 2 weeks of vaccination.”It’s clear why Livshits continues to take a bullish stance. In addition to keeping a Buy recommendation on the stock, the price target remains at $10. The implication for investors? Upside potential of 150%. (To watch Livshits’ track record, click here) With 3 "buy" ratings against just 1 "hold," PDSB shares have earned their Strong Buy consensus rating. Meanwhile, the $7.32 average price target implies shares could climb 83% higher in the next twelve months. (See PDSB stock analysis on TipRanks)GlycoMimetics (GLYC)Hoping to improve the lives of patients with unmet medical needs, GlycoMimetics develops small-molecule glycomimetic product candidates. According to Wall Street analysts, at $3.86, its share price could present investors with an opportunity to get in on the action.Standing squarely with the bulls is Roth Capital’s Zegbeh Jallah. Following the analyst’s virtual meeting with the management team, he is confident in GLYC’s long-term growth prospects.Pointing to GLYC’s Phase 3 Rivipansel asset, which was designed as a treatment for patients with Sickle Cell, Jallah argues that there is a substantial market opportunity. In the U.S., there are roughly 100,000 sickle cell patients, with some of these hospitalized 1-3 times per year for painful vaso-occlusive crisis (VOCs). Opioids are the current standard of care, but there are significant concerns regarding dependency. “We believe that a need exists for treatment options that can lessen the risks associated with opioid use, without leaving patients in pain,” the analyst commented.Currently, Rivipansel, an IV-delivered, pan-selectin antagonist, is the only therapy being clinically developed for this application. It differs from Novartis’ Crizanlizumab, a p-selectin antibody that is used to prevent VOCs, as p-selectin plays an earlier role than other selectins. “With Rivipansel more potent against e-selectin and with a half-life of 8 hours, Phase 1 data showed that its benefits were present after the onset of a VOC,” Jallah explained.As for the Phase 2 study, the results were also encouraging. However, in the Phase 3 study, the drug failed to meet its primary endpoint of time to readiness-to-discharge. That being said, Jallah still has high hopes.
- 08/06/2020
|
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
- FLORHAM PARK, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executive Officer, Michael King, Interim Chief Financial Officer, and Dr. Lauren Wood, Chief Medical Officer will host a conference call to review the financial results and provide a business update. The conference call is scheduled to begin at 8:00 am ET on Thursday, August 13, 2020. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.pdsbiotech.com.After the live webcast, the event will be archived on PDS Biotech’s website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13707451.About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.Media & Investor Relations Contact:Deanne Randolph PDS Biotech Phone: +1 (908) 517-3613 Email: drandolph@pdsbiotech.comAlexander Lobo The Ruth Group Phone: +1 (646) 536-7037 Email: alobo@theruthgroup.com
- 07/30/2020
|
PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19
- Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccinationFLORHAM PARK, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203). PDS0203 pairs the Versamune® platform with a recombinant protein recognized by the human immune system that is derived from the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus that causes COVID-19. The protein included in PDS0203 encompasses SARS-CoV-2 sections that induce an antibody response, as well as sections that are recognized by CD8 and CD4 T-cells. PDS Biotech has generated robust preclinical data confirming that PDS0203 elicits induction of highly active and potent virus-specific CD8 killer and CD4 helper T-cells within 14 days of treatment. Importantly, the study also demonstrated induction of the long-lasting virus-specific memory T-cells necessary for longer term protection. PDS0203 demonstrated a 30-45 fold increase in COVID-19 specific T-cells by Day 14 when compared to the vaccine without Versamune®. These preclinical studies also confirmed induction of strong anti-SARS-CoV-2 neutralizing antibodies within 14 days, with a 20-25-fold increase when compared to the vaccine without Versamune®. Lastly, these preclinical studies showed a further substantial increase in neutralizing antibody levels continuing more than 30 days after vaccination. PDS Biotech plans to submit details of the preclinical studies to a peer reviewed scientific journal."Recent COVID-19 research has highlighted the critical importance of developing vaccines capable of generating high levels of targeted CD8 and CD4 T-cells, in addition to neutralizing antibodies, to achieve durable protection against COVID-19 infection. Our preclinical data shows PDS0203’s ability to rapidly induce both protective antibodies and long-lasting T-cells specific for COVID-19,” commented Dr. Frank Bedu-Addo, CEO of PDS Biotech, “Due to the mechanism by which Versamune® activates a disease-specific immune response, our PDS0101 program demonstrated successful translation of T-cell induction and safety data from preclinical models to humans. We therefore believe that this encouraging PDS0203 preclinical data may similarly translate to humans. If so, then it may present unique potential to provide the breadth and level of immune responses necessary for a safe and effective vaccine with long-term protection against COVID-19."As previously announced, the Company has also initiated preclinical development of Versamune®-CoV-2FC (PDS0204), a COVID-19 vaccine candidate being developed in partnership with Brazil-based Farmacore Biotechnology, which combines the immune-activating Versamune® platform with a Farmacore-developed SARS-CoV-2 recombinant fusion protein.About the Versamune® technology platformThe Versamune® technology is based on proprietary immune activating lipids that uniquely activate an important immunological signaling pathway, called the Type 1 interferon signaling pathway, known to be important in the induction of both anti-viral and anti-tumor immune responses. It also promotes efficient access of the disease-specific immunologically recognized protein (antigen) into two important immunological pathways called the Class I and II MHC pathways, therefore enabling powerful induction and activation if CD8 (Killer) and CD4 (helper) T-cells that can recognize, kill and protect against the specific disease. The technology is protected by multiple international composition and application patents.About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.About PDS0203PDS0203 is a COVID-19 vaccine candidate that combines the utility of the Versamune® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein. The World Health Organization (WHO) declared the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread. Building immunity to the disease is the key to stopping its spread. A COVID-19 vaccine would train the immune system to recognize and destroy the virus without the vaccinated person getting sick.About PDS0204PDS0204 is a COVID-19 vaccine candidate that combines the utility of the Versamune® platform with a Farmacore-developed recombinant fusion protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread. Building immunity to the disease is the key to stopping its spread. A COVID-19 vaccine would train the immune system to recognize and destroy the virus without the vaccinated person getting sick.Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101; the preclinical results of the Company’s PDS0203 and PDS0204 product candidates, which will be subject to more rigorous testing and which are not necessarily indicative of future clinical results; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and PDS0204, and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved, and the overall performance and success of the Company’s product candidates; the number or type of studies or nature of results necessary to support the filing of a new drug application for any of the Company’s current product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC.
- 07/27/2020
|
Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration
- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the Phase III Archway study evaluating its i
- 07/22/2020
|
Sustenance vs Succour: With political will, PDS can be reformed
- Weekly DBT through biometric-enabled electronic debit cards can be considered
- 07/20/2020
|
PDS Biotechnology (NASDAQ:PDSB) Upgraded to Hold at Zacks Investment Research
- Zacks Investment Research upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, […]
- 07/19/2020
|
HC asks Delhi govt why it cannot continue its lockdown foodgrain distribution scheme
|
PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine
- PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS0201 for tuberculosis and PDS0203 for COVID-19FLORHAM PARK, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that PDS Biotech collaborator, Professor J. Woodward of the University of Kentucky School of Medicine, has been awarded a grant from the National Institute of Allergy and Infectious Diseases’ (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) program to progress development of a Versamune®-based universal influenza vaccine. The key objective of the NIAID’s CIVICs program is to develop more durable, broadly protective, and longer-lasting vaccines effective against multiple strains of influenza, specifically including pandemic strains. Under the award, PDS Biotech will continue development of its PDS0202 vaccine program, which combines Versamune® with novel influenza vaccine antigens, with a goal of rapidly progressing into a human clinical trial. Preclinical development studies will be performed at three sites: PDS Biotech’s Princeton, NJ laboratories, The University of Kentucky School of Medicine, and the CIVICs Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP). “We are excited to accelerate PDS0202 development to further demonstrate Versamune®’s ability to induce the immune system to generate high levels of neutralizing antibodies, killer T-cells, and long acting memory T-cells, that for PDS0202 could provide broad and long-term protection against multiple influenza strains,” commented Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. “NIAID support for the upcoming PDS0202 preclinical studies could speed development of a more durable and broadly protective influenza vaccine, thus reducing the public health consequences of both seasonal and pandemic influenza.”PDS Biotech’s infectious disease portfolio consists of PDS0201 (tuberculosis), PDS0202 (universal flu) and PDS0203 (COVID-19), all of which are based on the Versamune® platform and are designed to induce a broad range of long-term protective immune responses against these pathogens.About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.About PDS0201PDS0201 is an investigational vaccine designed for the prevention of tuberculosis. PDS0201 combines the utility of the Versamune® platform with bacillus Mycobacterium tuberculosis (M. tuberculosis) antigens. Tuberculosis (TB) is the leading cause of death from a single infectious agent and is caused by the bacillus M. tuberculosis, which is spread when people who are sick with TB expel bacteria into the air. About a quarter of the world’s population is infected with M. tuberculosis and thus at risk of developing TB disease. PDS0201 is currently in preclinical development.About PDS0202PDS0202 is an investigational vaccine designed for the prevention of a broad range of influenza strains. PDS0202 combines the utility of the Versamune® platform with a mix of influenza antigens including conserved regions of the virus. Influenza is estimated to result in about 3 to 5 million cases of severe illness, and about 290,000 to 650,000 respiratory deaths globally. Some strains of influenza are known to have strong pandemic potential. PDS0202 is currently in preclinical development.About PDS0203PDS0203 is a COVID-19 vaccine candidate that combines the utility of the Versamune® platform with a mix of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antigens. The World Health Organization (WHO) declared the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread. Building immunity to the disease is the key to stopping its spread. A COVID-19 vaccine would train the immune system to recognize and destroy the virus without the vaccinated person getting sick. PDS0203 is currently in preclinical development.Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.Media & Investor Relations Contact:Deanne Randolph PDS Biotech Phone: +1 (908) 517-3613 Email: drandolph@pdsbiotech.comTram Bui / Alexander Lobo The Ruth Group Phone: +1 (646) 536-7035 / +1 (646) 536-7037 Email: tbui@theruthgroup.com / alobo@theruthgroup.com
- 07/14/2020
|
One Nation, One Ration Card' scheme launched in Jammu and Kashmir's Rajouri
- One Nation One Nation Card is an initiative by the Government of India which enables ration cardholders to access PDS benefits from any fair price shop in the country.
- 07/14/2020
|
How to build an ETF portfolio in Australia, with Kris Walesby of ETF Securities | Rask Media
- With so many choices available on the ASX in 2020, how do you build an ETF portfolio with Australian and international shares, gold and silver, bonds and... everything else?
- 07/13/2020
|
ADAS Market by System, Component, Vehicle, Level of Autonomy, Offering, EV, and Region - Global Forecast to 2030 - ResearchAndMarkets.com
|
Tripura government cancels 62340 fake ration cards in state
|
Halliburton: Take The Profits And Wait For The Next Leg Down (NYSE:HAL)
- Halliburton has enjoyed an impressive rally off its bottom in March. While the price of oil has rallied to a 4-month high, the recovery of shale oil production is not expected until the second half of next year.
- 07/06/2020
|
Opinion: PM's One-Nation, One-Ration Scheme - What Not To Do
|
Flour millers seek 23% cut in wheat price under open market sale scheme
- As per weather reports, kharif 2020 is going to be normal and next rabi crop also may be bumper. So, the storage gap will eventually widen.
- 07/03/2020
|
2 Australian shares ETFs for 2020 & beyond | Rask Media
- The Betashares Australia 200 ETF (ASX: A200) and Vanguard Australian Shares Index ETF (ASX: VAS) are two of the most popular Australian shares ETFs that might be worth digging into in 2020. Here's what you need to know...
- 07/02/2020
|
VanEck: EM history repeats itself | Rask Media
- Despite recent underperformance, emerging markets look compelling from a valuation standpoint and could benefit from the unprecedented stimulus policies.
- 07/02/2020
|
Here are 6 reasons to add Telstra shares to your ASX watchlist | Rask Media
- As a change of pace, I've taken a look at the outlook for Telstra Corporation Ltd (ASX: TLS) both during and post COVID-19.
- 07/02/2020
|
S&P/ASX 200 to open higher - stocks to watch | Rask Media
- The S&P/ASX 200 (INDEXASX: XJO) is set to open higher on Thursday, building on the positive start to the new financial year. Here's what you need to know.
- 07/01/2020
|
Willing to make sanitary napkins ‘essential commodity’ but not without consulting all stakeholders: Centre to Bombay HC
- The Centre said the petitioners have made a sweeping allegation that the government machineries were not working properly during the lockdown.
- 07/01/2020
|
Will the end of JobKeeper impact Xero? | Rask Media
- Xero (XRO: ASX), the provider of cloud-based accounting software, could be nervous about how fast September is approaching. Here's why.
- 07/01/2020
|
Is Temple & Webster (TPW) the best ecommerce ASX share? | Rask Media
- Temple & Webster (ASX:TPW) is doing a capital raising. Is it the best ecommerce ASX share?
- 07/01/2020
|
S&P/ASX 200 opens higher - earnings season up ahead | Rask Media
- The S&P/ASX 200 (INDEXASX: XJO) is following the lead of US markets to push higher on Wednesday as we venture into a new financial year.
- 07/01/2020
|
June 2020 house prices drop, what does it mean for ASX shares? | Rask Media
- Some ASX shares are down after CoreLogic reported that house prices dropped in June 2020. The decline accelerated compared to May.
- 07/01/2020
|
More contract wins for Nextdc (ASX:NXT), shares jump 7% | Rask Media
- Nextdc (ASX:NXT) announced more contract wins for its NSW data centre facilities. Nextdc shares are up 7% in early trading.
- 07/01/2020
|
New business plan: Are Suncorp (ASX:SUN) shares a buy? | Rask Media
- Suncorp (ASX:SUN) has announced a new operating model for its business. Are Suncorp shares a buy?
- 06/30/2020
|
AMP (ASX:AMP) completes $3 billion sale. Dividend incoming? | Rask Media
- AMP (ASX:AMP) has announced it has finished its $3 billion sale. Is it going to pay a dividend?
- 06/30/2020
|
At least 10 kg ration required per month to prevent hunger deaths: Left parties on PMGKAY extension
- The Left parties on Tuesday said Prime Minister Narendra Modi extending the PMGKAY scheme to provide 5 kg free ration to the needy is not enough as 10 kg per month is required to prevent hunger deaths.
- 06/30/2020
|
PM Narendra Modi extends free foodgrains scheme for poor till Nov-end
- Earlier, under the first phase of Garib Kalyan Yojana, 12 million tonnes of grains was allocated for the three months of April, May and June
- 06/30/2020
|
One Nation One Ration card to be reality soon, actively working on it: PM Modi
- The universal ration card 'One Nation One Ration Card' can be used across the country.
- 06/30/2020
|
PM Modi: One Nation One Ration Card scheme being actively worked upon
- Prime Minister Narendra Modi during his address to the nation said that the government was actively working on One Nation One Ration Card Scheme. He said that the scheme is being developed so that those living outside their home states get the benefit of Public Distribution System (PDS).
- 06/30/2020
|
Live updates | Narendra Modi Address to Nation: PM Speech Live Updates - Full coverage
- PM Modi Address to nation: Amid Unlock 2.0 getting implemented from tomorrow and rising China-US tensions, PM Narendra Modi is addressing the nation.
- 06/30/2020
|
FY20 report: Collins Foods (CKF) shares jump 17% | Rask Media
- The Collins Foods (ASX:CKF) share price jumped 17% today after releasing its FY20 result.
- 06/30/2020
|
Freedom Foods (ASX:FNP) announces management change | Rask Media
- Freedom Foods (ASX:FNP) has announced that there's going to be a management change at the top.
- 06/30/2020
|
Brickworks (BKW) & Goodman (GMG) just signed on Amazon | Rask Media
- Brickworks (ASX:BKW) and Goodman (ASX:GMG) have just announced that Amazon has signed on to be another major tenant.
- 06/30/2020
|
Are $18, are ANZ shares finally cheap? | Rask Media
- It's been a big year for bank shareholders, but none more so than ANZ Banking Group (ASX: ANZ) shareholders.
- 06/30/2020
|
Why Lifestyle Communities (LIC) is one ASX share to watch | Rask Media
- I think Lifestyle Communities (ASX:LIC) is one ASX share to watch after making an announcement today.
- 06/30/2020
|
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.85%
- U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.85%
- 06/30/2020
|
WiseTech (ASX:WTC) founder sells $45 million of shares | Rask Media
- WiseTech Global (ASX:WTC) shares will be under scrutiny this morning after its CEO and founder sold $45 million of shares.
- 06/29/2020
|
S&P/ASX 200 index to pop Tuesday morning - stocks to watch | Rask Media
- The S&P/ASX 200 (INDEXASX: XJO) is expected to jump this morning, according to data from the Sydney Futures Exchange. Here's everything you need to know.
- 06/29/2020
|
-$0.13 Earnings Per Share Expected for Precision Drilling Corp (NYSE:PDS) This Quarter
- Wall Street brokerages predict that Precision Drilling Corp (NYSE:PDS) (TSE:PD) will announce earnings per share of ($0.13) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Precision Drilling’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.17). Precision Drilling […]
- 06/29/2020
|
Dramatically increase access and affordability: Aadhaar chief architect on India's digital infrastructure
- In April and May, during an exodus unlike anything seen in India since Partition in 1947, India's migrant workers, the backbone of the country's labour force, spilled out of big cities that were shuttered and willed themselves to walk back hundreds of miles to their homes.
- 06/29/2020
|
Monash IVF (MVF) says the IVF market is recovering | Rask Media
- Monash IVF (ASX:MVF) shares are down 1% despite announcing that it is seeing a recovery in the IVF market.
- 06/29/2020
|
How Tabcorp (TAH) just sent Jumbo (JIN) shares down 11% | Rask Media
- Tabcorp (ASX:TAH) shares are up 2% and Jumbo (ASX:JIN) shares are down 11% after some changes were announced.
- 06/29/2020
|
Bidding war continues for Infigen (ASX:IFN) | Rask Media
- The bidding war for Infigen (ASX:IFN) continues as two more bids emerged this morning.
- 06/29/2020
|
FY20 result: Fisher & Paykel Healthcare (FPH) grows profit by 37% | Rask Media
- Fisher & Paykel Healthcare (ASX:FPH) has announced its FY20 full year result for the 12 months to 31 March 2020.
- 06/29/2020
|
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.32%
- U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.32%
- 06/29/2020
|
S&P/ASX 200 (XJO) today - ASX shares to watch closely | Rask Media
- The S&P/ASX 200 (INDEXASX: XJO) is expected to open lower on Monday morning according to the Sydney Futures Exchange.
- 06/28/2020
|
My top 6 changes for ASX share investors before June 30th | Rask Media
- With the 2019/2020 tax year coming to its end on Tuesday, as a financial planner I think it's worth reflecting on what we have just experienced and some of the steps to take now, before June 30th
- 06/28/2020
|
In Jharkhand, social audit finds nearly half the people didn’t get full lockdown ration
- These are some of the findings mentioned in a report prepared by Jharkhand’s Social Audit Unit, under the Rural Development Department, created to “promote transparency and accountability in implementation of the programs”.
- 06/27/2020
|
India coronavirus dispatch: Poor spending heightens vulnerability to crisis
- Mizoram enforces Lockdown 7.0, Hyderabad suspends Covid testing, and stroke, depression, anxi-ety in Covid patients - a roundup of news on how India is dealing with the pandemic
- 06/26/2020
|
It looks like Virgin (ASX:VAH) is about to have a new owner | Rask Media
- It seems that Virgin Australia (ASX:VAH) is about to have a new owner after Cyrus Capital pulled out of the running.
- 06/26/2020
|
Freedom Foods (FNP) gives update, outlines writedowns | Rask Media
- Freedom Foods (ASX:FNP) has given an update and outlined some writedowns.
- 06/26/2020
|
ASX 200 today - my thoughts on QAN capital raising & latest GDP | Rask Media
- The S&P/ASX 200 (INDEXASX: XJO) index is expected to open higher today, with Qantas (ASX: QAN) and Macquarie Group (ASX: MQG) shares in focus. Here's what you need to know...
- 06/25/2020
|
Qantas (ASX:QAN) completes $1.36 billion raising, time to buy shares? | Rask Media
- Qantas (ASX:QAN) has announced that it has completed the institutional part of its capital raising.
- 06/25/2020
|
A time to universalise PDS
- That foodgrain stocks lie in public godowns while people are going hungry is a scandal.
- 06/25/2020
|
Was I dead wrong about The Trade Desk (NASDAQ:TTD) stock? | Rask Media
- I sold my The Trade Desk (NASDAQ: TTD) stock during the 'COVID crash'... only for it to go up 100%. But that's not all...
- 06/25/2020
|
The Redbubble (ASX:RBL) share price is going nuts | Rask Media
- Redbubble (ASX:RBL) shares are going nuts, it's currently up around 40%.
- 06/25/2020
|
Bapcor (ASX:BAP) revs up growth | Rask Media
- Bapcor (ASX:BAP) has reported impressive growth for May and June, higher than expected.
- 06/25/2020
|
Active govt intervention needed in hunger relief efforts, says IIM-A study
- The report highlights that insufficient funding remains an obstacle to hunger relief efforts by organisations and individuals. More than 87 per cent of the respondents claimed that funding was their primary concern and it might compel them to suspend operations.
- 06/25/2020
|
Accent (ASX:AX1) update: Time to buy shares? | Rask Media
- Accent (ASX:AX1) has given investors an update today, is it time to buy shares?
- 06/25/2020
|
CSL (ASX:CSL) reveals US$450 million acquisition | Rask Media
- CSL (ASX:CSL) has announced a US$450 million acquisition to the market, AMT-061.
- 06/24/2020
|
Qantas (ASX:QAN) announces huge capital raising | Rask Media
- Qantas (ASX:QAN) has announced a very big capital raising this morning. It's asking investors for $1.9 billion.
- 06/24/2020
|
ASX 200 to fall at the open, 8 ASX shares to watch | Rask Media
- The S&P/ASX 200 (INDEXASX: XJO) or ASX 200 is expected to open lower on Thursday morning, with the Sydney Futures Exchange showing firmly lower contract values.
- 06/24/2020
|
Existence of Two Giant Newborn Planets in PDS 70 System Confirmed by Astronomers
- New Direct Images Captured with W. M. Keck Observatory’s Upgraded Adaptive Optics System Lead to First Independent Confirmation of PDS 70 Protoplanets New evidence shows the first-ever pictures capturing the birth of a pair of planets orbiting the star PDS 70 are in fact authentic. Using a new
- 06/24/2020
|
CSR (ASX:CSR) reveals FY21 trading update at AGM | Rask Media
- CSR (ASX:CSR) has announced a FY21 trading update during its annual general meeting (AGM).
|
